New drug aims to slow kidney failure in chronic disease patients
Disease control
Completed
This completed trial tested a new drug called QRX-3 (Eseronate) in 45 people with chronic kidney disease stages 3-5. The goal was to see if the drug could slow the decline in kidney function and reduce protein in the urine. The study compared changes in kidney function over time.
Sponsor: Neukidney Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:48 UTC